Fresenius Kabi
- Country
- 🇧🇪Belgium
- Ownership
- Subsidiary
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- -
Short-term Metabolic Effects of Ketosteril® Supplemented Low Protein Diet in Pre-dialysis Chronic Kidney Disease (CKD) Patients
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 23
- Registration Number
- NCT03077048
- Locations
- 🇨🇿
Thomayer Hospital Clinical - Pharmacology Unit (CPU), Prague, Czechia
Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 24
- Registration Number
- NCT02968498
- Locations
- 🇩🇪
CRO BioTeSys GmbH, Esslingen, Germany
Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Free Intake
- Conditions
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 20
- Registration Number
- NCT02938234
- Locations
- 🇩🇪
SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt, Thuringia, Germany
Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Scheduled Intake
- Conditions
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 20
- Registration Number
- NCT02938247
- Locations
- 🇩🇪
SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt, Thuringia, Germany
Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 266
- Registration Number
- NCT02795039
- Locations
- 🇨🇦
BioPharma Services Inc., Toronto, Ontario, Canada
🇨🇦Algorithme Pharma Inc., Mount Royal, Quebec, Canada
🇨🇦Lambda Therapeutic Research Inc., Toronto, Ontario, Canada
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
- Conditions
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 154
- Registration Number
- NCT02756520
- Locations
- 🇨🇳
Prof. Xiangmei, Beijing, Beijing, China
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-027-CNI)
- Conditions
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 85
- Registration Number
- NCT02746133
Observational Study on Chronic Kidney Disease Treatment With a Ketosteril Supplemented Protein-restricted Diet
- Conditions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 164
- Registration Number
- NCT02649205
- Locations
- 🇭🇺
Velencei-tavi Kistérségi Járóbeteg Szakellátó Közhasznú Nonprofit Kft, Velence, Hungary
Screening Day Latin America
- Conditions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 1162
- Registration Number
- NCT02583880
- Locations
- 🇦🇷
Sanatorio Norte, San Salvador de Jujuy, Jujuy, Argentina
🇦🇷Hospital Eva Perón, Granadero Baigorria, Rosario, Argentina
🇦🇷Hospital Británico, Caba, Buenos Aires, Argentina
Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 204
- Registration Number
- NCT02579265
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Lucile Packard Children's Hospital, Palo Alto, California, United States
🇺🇸Steven & Alexandra Cohen Children's Medical Center of NY, New York, New York, United States